; doi:10.1152/ajprenal.00548.2014.-There is good evidence for a causal link between excessive sympathetic drive to the kidney and hypertension. We hypothesized that sympathetic regulation of tubular Na ϩ absorption may occur in the aldosteronesensitive distal nephron, where the fine tuning of renal Na ϩ excretion takes place. Here, the appropriate regulation of transepithelial Na ϩ transport, mediated by the amiloride-sensitive epithelial Na ϩ channel (ENaC), is critical for blood pressure control. To explore a possible effect of the sympathetic transmitter norepinephrine on ENaC-mediated Na ϩ transport, we performed short-circuit current (Isc) measurements on confluent mCCDcl1 murine cortical collecting duct cells. Norepinephrine caused a complex I sc response with a sustained increase of amiloride-sensitive Isc by ϳ44%. This effect was concentration dependent and mediated via basolateral ␣ 2-adrenoceptors. In cells pretreated with aldosterone, the stimulatory effect of norepinephrine was reduced. Finally, we demonstrated that noradrenergic nerve fibers are present in close proximity to ENaC-expressing cells in murine kidney slices. We conclude that the sustained stimulatory effect of locally elevated norepinephrine on ENaC-mediated Na ϩ absorption may contribute to the hypertensive effect of increased renal sympathetic activity.
epithelial Na ϩ channel; epithelial sodium transport; norepinephrine; renal sympathetic innervation; collecting duct ESSENTIAL HYPERTENSION originates, by definition, without a single known cause and is treated using drug regimens to target various effectors that lower blood pressure. Excessive sympathetic drive may contribute to some forms of hypertension (28) , but the complex mechanisms by which renal sympathetic innervation contributes to the long-term control of arterial blood pressure remain incompletely understood.
The renal nerves are known to regulate several key renal functions, including renin secretion and tubular reabsorption of solutes along the nephron as well as renal blood flow and, therefore, glomerular filtration rate (13) . Renal nerves follow the major renal arterial vessels and supply not only the vasculature but also the juxtaglomerular apparatus and basement membrane of epithelial cells lining the tubules of the nephron (2). These sympathetic nerve fibers release norepinephrine as well as cotransmitters including neuropeptide Y and ATP (7, 34) .
An important link between the renal nerves and renal Na ϩ handling was demonstrated in early animal studies. Both reflex and direct stimulation of renal nerves in anesthetized animals resulted in a reduced fractional excretion of Na ϩ in the absence of changes to glomerular filtration rate or renal blood flow. These effects could be prevented using the sympathetic blocker guanethidine, the ␣-adrenoceptor antagonist phenoxybenzamine, or surgical renal denervation (1, 38, 39) . Sympathetic nerves may have a direct stimulatory effect on Na ϩ absorption along the length of the nephron (12) . Indeed, studies in isolated renal tubules have provided evidence that adrenergic effectors, including norepinephrine or adrenoceptor agonists, can stimulate Na ϩ absorption in the proximal tubule (4, 31) as well as in cells isolated from the distal convoluted tubule (23) . However, the underlying mechanisms are not yet fully understood and may vary within different tubular segments.
Sympathetic regulation of tubular Na ϩ transport may be of particular importance in the aldosterone-sensitive distal nephron (ASDN), a critical nephron segment for the fine tuning of renal Na ϩ excretion. The ASDN comprises the late distal convoluted tubule, connecting tubule, and collecting duct and represents the nephron segment where fine tuning of renal Na ϩ absorption is accomplished and is under tight regulation by aldosterone and other factors (30) . The epithelial Na ϩ channel (ENaC) marks the rate-limiting step of this process, and the importance of this channel for long-term control of blood pressure is highlighted by monogenic diseases caused by mutations in the channel. These include Liddle's syndrome, a severe form of salt-sensitive hypertension, and pseudohypoaldosteronism 1, a salt wasting disease (35, 36) .
The aim of the present study was to determine whether ENaC-mediated Na ϩ transport in the mammalian collecting duct can be modulated by the sympathetic transmitter norepinephrine. To accomplish this, we used highly differentiated murine principal cells (mCCD cl1 ) derived from the microdissected cortical collecting duct (20) . This cellular model offers a system by which ENaC-mediated Na ϩ transport and its regulation can be evaluated using the Ussing chamber technique.
METHODS
Cell culture. mCCDcl1 cells were kindly provided by Bernard Rossier (University of Lausanne, Lausanne, Switzerland) and were routinely cultured in phenol-red free DMEM-F-12 medium supplemented with FBS (2%), triiodothyronine (1 nmol/l), sodium selenite (60 nmol/l), apotransferrin (5 g/ml), EGF (10 ng/ml), insulin (5 g/ml), dexamethasone (50 nmol/l), penicillin (100 U/ml), and streptomycin (100 g/ml), as previously described (20) . Cells were used between passages 29 and 33 and were grown for 9 -11 days on polycarbonate membrane inserts (Millipore). After 5 days, cells were fed with media with apotransferrin, EGF, and FBS removed. For the final 24 h, dexamethasone was removed (experimental medium). The transepithelial potential difference (V te) and resistance (Rte) of cells grown on inserts were routinely monitored using an epithelial voltohm-meter with a set of two sticks "STX" electrodes (World Precision Instruments).
Ussing chamber recordings. Cells to be used for transepithelial measurements were seeded onto 12-mm polycarbonate membrane inserts, transferred to Ussing chambers on days 9 -11, and bathed in experimental medium. Modified small-volume Ussing chambers were kept at 37°C in an incubator containing 5% CO 2. Transepithelial measurements were made under open circuit conditions, as previously described (5), where Vte was continuously recorded using a CVC6 clamp device (Fiebig, Berlin, Germany). Rte was evaluated every 2-10 s by measuring voltage deflections induced by injecting 0.4 s symmetrical square pulses of 3 A. The equivalent short-circuit current (I sc) was then calculated using Ohm's law. By convention, a positive Isc reflects either electrogenic absorption of cations, electrogenic secretion of anions, or a combination of both. Amiloride was applied to the apical bath at the end of each experiment to inhibit ENaC-mediated Na ϩ transport; both 10 and 100 mol/l were used. Ethical approval for animal experiments. For the present study, tissue preparations were obtained from a total of six C57BL/6 mice (Mus musculus). Animals were cared for and experiments were performed in accordance with the principles of German legislation. Experiments were approved by the animal welfare officer of the Friedrich-Alexander-Universität Erlangen-Nürnberg (license numbers: TS-03/01 ZellPhys and TS-99/20 Anatomie I). Care and housing of the animals was under the governance of the state veterinary health inspectorate.
Immunohistochemistry. Three mice were euthanized with CO 2 followed by an overdose of thiopental (Trapanal, 250 mg/kg ip, Byk Gulden, Konstanz, Germany) and transcardially perfused with buffered 4% paraformaldehyde. Sections of the kidneys were cut on a cryostat, postfixed on a slide in ice-cold acetone, and rinsed in Tris-buffered saline (TBS). After preincubation for 1 h at room temperature in TBS containing 1% BSA, 0.5% Triton X-100, and 5% donkey normal serum, sections were rinsed in TBS and incubated with a polyclonal rabbit antibody directed against mouse ␤-ENaC (26) (1:250) combined with a sheep antibody against mouse tyrosine hydroxylase (Novus Biological, 1:2,000) or a guinea pig antibody directed against the pan neuronal marker protein gene product 9.5 (Fitzgerald, 1:500) in TBS containing 1% BSA and 0.05% Triton X-100 overnight at room temperature. Controls for specificity of the tyrosine hydroxylase antibody were performed by preabsorption with 2 g/100 ml of the respective antigen (Novus Biological) for 24 h at room temperature. After a further TBS rinse, secondary antibodies (donkey anti-rabbit Alexa 488 and donkey anti-sheep Alexa 555, both from Molecular Probes, 1:1,000 in TBS) were applied for 1 h at room temperature. After a final rinse, sections were mounted in TBSglycerol (pH 8.6). Single optical sections were imaged using a Nikon Eclipse C1 confocal laser scanning system (Nikon, Tokyo, Japan) equipped with a 488-nm argon laser and a 543-nm helium-neon laser (both from Melles Griot). Dry objectives (ϫ20, numerical aperture: 0.75, and ϫ40, numerical aperture: 0.95) were used.
RT-PCR.
Total RNA was extracted from mCCD cl1 cells cultured on permeable supports (consistent with transepithelial measurements) as well as from the mouse brain, liver, and aorta using the NucleoSpin RNA Kit-XS (Macherey & Nagel) according to the manufacturer's instructions. Mouse tissue samples were obtained from three animals euthanized by CO 2 inhalation followed by terminal interruption of circulation. Lysates from four 0.6 cm 2 cell culture plate inserts were pooled to enhance the RNA concentration. The purity of RNA was verified by the 260-to-280-nm optical density ratio. cDNA was synthesized from 0.5 g RNA and amplified with specific primers against the coding sequence of each mouse adrenoceptor subtype as well as ␤-ENaC using the RNA Reverse Transcription System Kit (Promega, Mannheim, Germany). Specific primers were designed (Table 1) according to sequence data stated in the National Center for Biotechnology Information gene databank and were synthesized by biomers. net (Ulm, Germany). All reactions were carried out in a MJ-Research PTC-200 Peltier Thermo Cycler (Biozym, Hessisch Oldendorf, Germany). Amplified PCR products were separated by agarose gel electrophoresis (3.5% universal agarose, Bio&Sell, Feucht, Germany) and stained by ethidium bromide.
Data analysis. Data are expressed as means Ϯ SE; n values refer to the number of times the experiment was repeated and, unless otherwise stated, are labeled in parentheses within bar diagrams. Single experiments were matched as closely as possible according to passage number, time, culture, and experimental conditions. Data were analyzed using GraphPad Prism 5.04 (GraphPad Software). Statistical significance was assessed using either a Student's paired or unpaired t-test or one-way ANOVA with a Bonferroni post hoc test.
RESULTS

Basolateral addition of norepinephrine causes a complex I sc response with a sustained stimulatory effect on ENaC-mediated transepithelial Na
ϩ transport. Baseline I sc in mCCD cl1 cells (Fig. 1A ) averaged 6.9 Ϯ 0.7 A/cm 2 , and R te was 4.9 Ϯ 0.2 k⍀·cm 2 (n ϭ 42), consistent with a previous report (20) . Application of amiloride (10 mol/l) to the apical bath inhibited I sc by 94 Ϯ 3%, indicating that basal I sc can be attributed to electrogenic Na ϩ absorption via ENaC. Addition of norepinephrine (10 mol/l) to the basolateral bath modulated I sc in a complex manner involving three phases (Fig. 1B ). An immediate peak response of 1.8 Ϯ 0.1 A/cm 2 was seen in the first phase, returning to baseline within 1 min. This was followed by a transient decrease by 1.9 Ϯ 0.1 A/cm 2 within ϳ15 min. Over the subsequent 2.5 h, I sc gradually increased by 2.5 Ϯ 0.2 A/cm 2 above baseline (n ϭ 71, P Ͻ 0.001; Fig. 1C ). In contrast, I sc was not affected in vehicle-treated cells (Fig. 1A) or when norepinephrine was added to the apical bath (data not shown). To estimate ENaC-mediated I sc , I sc determined in the presence of amiloride was subtracted from I sc measured in its absence. At the base of the norepinephrine-induced transient decrease, amiloride-sensitive I sc was reduced by 22 Ϯ 1% (n ϭ 16, P Ͻ 0.001) with no significant change in time-matched, vehicle-treated controls (n ϭ 16; Fig. 2A ). Importantly, in the presence of amiloride, norepinephrine had no effect on I sc except for eliciting an immediate peak response, most likely due to Cl Ϫ secretion via Ca 2ϩ -activated Cl Ϫ channels (Fig. 2B ) (5, 10). These findings indicate that both the norepinephrineinduced transient decrease and sustained increase in I sc can be attributed to changes in ENaC-mediated transepithelial Na ϩ transport. On average, the basolateral addition of norepinephrine resulted in a sustained stimulation of ENaC-mediated I sc by 44 Ϯ 4% (n ϭ 71, P Ͻ 0.001) with no significant change observed in vehicle-treated controls (n ϭ 42). The effects of norepinephrine were concentration dependent, with significant transient inhibition and sustained stimulation observed at 100 nmol/l and 1 mol/l, respectively (Fig. 3) .
␣ 2 -Adrenoceptors mediate the modulation of ENaC activity by norepinephrine. To determine the adrenoceptors responsible, cells were treated with either vehicle or adrenoceptor antagonist for 30 min before the basolateral addition of norepinephrine (10 mol/l) for 2.5 h. None of the antagonists tested significantly altered baseline I sc (data not shown). Application of the ␤-adrenoceptor antagonist propranolol (1 mol/l) had no effect on the response to norepinephrine (Fig. 4A ), but treatment with the ␣-adrenoceptor antagonist phentolamine (20 mol/l) abolished all three components of the norepinephrine response (Fig. 4B) . To further classify which ␣-adrenoceptor was responsible, selective inhibitors were tested. The ␣ 1 -adrenoceptor antagonist prazosin (10 mol/l) did not modify the response to norepinephrine (Fig. 4C) ; however, the ␣ 2 -adrenoceptor antagonist RS-79948 (1 mol/l) abolished all three components of the response (Fig. 4D) .
mCCD cl1 cells express ␣ 2A -and ␣ 2C -adrenoceptor transcripts. To confirm these functional results at the transcript level, RT-PCR was used to determine the ␣-adrenoceptor profile in mCCD cl1 cells. None of the ␣ 1 -adrenoceptor subtypes (␣ 1A , ␣ 1B , or ␣ 1D ) were detected, but they were found in their respective positive controls (Fig. 5A) . Transcripts of ␣ 2A and ␣ 2C , but not ␣ 2B (Fig. 5B) , were detected in mCCD cl1 cells, and all were found in control tissues. It should be noted that a PCR product of 275 bp was detected with the ␣ 2A primers in addition to the expected product of 225 bp. This product, found in all samples, was excised, sequenced, and found to be rRNA. All other products were subsequently sequenced and corresponded to each of the adrenoceptors expected. Finally, transcripts of ␤-ENaC were detected in mCCD cl1 cells, as expected (Fig. 5C) .
Pretreatment with aldosterone alters the effects of norepinephrine on ENaC-mediated Na ϩ transport. The stimulatory effect of a physiological concentration of aldosterone (3 nmol/l) was confirmed in cells where I sc was increased by 189 Ϯ 14% (n ϭ 15, P Ͻ 0.01) compared with vehicle-treated cells after 3 h (Fig. 6) . In cells preincubated with aldosterone, a significantly stronger inhibition (P Ͻ 0.05) of I sc after norepinephrine treatment was observed, with a change in I sc (⌬I sc ) of Ϫ2.9 Ϯ 0.5 A/cm 2 (n ϭ 15) compared with a ⌬I sc of Ϫ1.4 Ϯ 0.1 A/cm 2 (n ϭ 15) in control cells not treated with aldosterone. In contrast, the sustained increase in I sc was significantly (P Ͻ 0.05) reduced in aldosterone-pretreated cells, with a ⌬I sc of 1.0 Ϯ 0.3 A/cm 2 compared with 2.2 Ϯ 0.5 A/cm 2 in vehicle-treated cells (Fig. 6) .
ENaC localizes in close proximity to adrenergic nerve fibers in kidney slices. Finally, experiments were carried out to determine whether ENaC-expressing cells are found within the vicinity of sympathetic nerve terminals at the tissue level. Kidney slices from mice were stained for ␤-ENaC, which is known to be exclusively expressed in principal cells of the ASDN, and for tyrosine hydroxylase, a marker for sympathetic nerve terminals. As shown in Fig. 7A , cells positively stained for ␤-ENaC localized in close proximity to tyrosine hydroxylase-stained nerves. Control experiments were performed to demonstrate the specificity of the tyrosine hydroxylase antibody (Fig. 7, B and C) . Moreover, the localization of neurons/nerve terminals was confirmed using an antibody against the pan neuronal marker protein gene product 9.5 (Fig. 8) .
DISCUSSION
This study demonstrates that norepinephrine has a sustained stimulatory effect on ENaC-mediated Na ϩ absorption in renal collecting duct principal cells. An inappropriate increase in ENaC activity is known to cause hypertension, as evidenced by gain of function mutations of the channel resulting in Liddle's syndrome. Therefore, stimulation of ENaC by norepinephrine may contribute to the development of high blood pressure, particularly in patients with increased renal sympathetic drive.
Our immunohistochemical data demonstrate that ENaCcontaining principal cells are located in close proximity to noradrenergic nerve fibers, suggesting that ENaC could be subject to regulation by locally released norepinephrine. This data correlates with early work by Barajas et al. (3) , who demonstrated that all tubular segments of the nephron come into contact with adrenergic nerve varicosities. A more recent study (29) has convincingly shown that noradrenergic nerves are found in close apposition to the basement membrane of collecting duct epithelial cells, with the narrowest gap recorded as 100 nm. Furthermore, the phenomenon of norepinephrine spillover from renal nerves may provide an additional indirect route by which norepinephrine could reach the basolateral membrane of principal cells (14) . As far as we know, the local norepinephrine concentration and stability of norepinephrine in this environment have not been determined. However, norepinephrine from the kidneys accounts for a substantial portion (ϳ25%) of total norepinephrine spillover in the body (15) . Thus, at rest, local norepinephrine concentrations in the vicinity of the tubular basement membrane may well reach levels similar to those measured in brain tissues (ϳ10 Ϫ9 mol/l) by a microdialysis study (17) . Moreover, renal norepinephrine spillover has been found to be increased in Na ϩ -depleted states and in essential hypertension (15) . Therefore, it is not unreasonable to speculate that under stimulated conditions, local concentrations ranging from 10 Ϫ9 to 10 Ϫ6 mol/l or even higher may be reached. It should also be noted that in vitro preparations often require higher agonist concentrations than those believed to be relevant in vivo. For example, arterial rings from the canine pulmonary artery require norepinephrine concentrations of Ͼ10 Ϫ4 mol/l to reach maximal contraction (18) . Thus, the relatively high concentrations of norepinephrine used in the present study do not preclude a physiological relevance of the observed effects. Therefore, under normal physiological conditions, it seems possible that fine tuning of Na ϩ absorption in the ASDN could be subject to sympathetic regulation.
Our functional experiments with adrenoceptor antagonists indicated that basolateral ␣ 2 -adrenoceptors are responsible for the complex effects of norepinephrine. In contrast, ␤-adrenoceptors do not seem to play a role, consistent with the finding that ␤-adrenoceptors are present only in intercalated but not principal cells of rat collecting ducts (8) . There are three subtypes of both ␣ 1 and ␣ 2 adrenoceptors: ␣ 1A,B,D and ␣ 2A,B,C . Transcripts of all subtypes have been detected in microdissected rat cortical collecting ducts (42) . However, these data cannot differentiate between populations of principal and intercalated cells. In isolated perfused collecting ducts, both epinephrine and the ␣ 2 -adrenoceptor agonist clonidine can inhibit the arginine vasopressin (AVP)-dependent production of cAMP, and this can be blocked with phentolamine and yohimbine but not prazosin. These studies provide functional evidence of ␣ 2 -adrenoceptors in AVP-responsive collecting duct principal cells (9, 33) . Using RT-PCR, we demonstrated the expression of ␣ 2A -and ␣ 2C -adrenoceptors, but not ␣ 2B -or ␣ 1A,B,D -adrenoceptors, in mCCD cl1 cells. Thus, ␣ 2A -and/or ␣ 2C -adrenoceptors are likely involved in mediating the effects of norepinephrine on ENaC. Interestingly, the inhibitory response was maximal at a norepinephrine concentration of 10 Ϫ7 mol/l, whereas the stimulatory response did not appear to reach saturation even at 10 Ϫ4 mol/l. These findings suggest that the two responses may be mediated via different receptors and/or different signaling pathways.
Activation of ␣ 2 -adrenoceptors is known to affect several intracellular signaling pathways, including a transient increase in intracellular Ca 2ϩ and a reduction in intracellular cAMP (41) . The signaling pathway responsible for the stimulatory effect of norepinephrine on ENaC remains to be determined. Interestingly, this stimulatory effect was preceded by two additional components: an amiloride-insensitive peak response and a transient reduction of amiloride-sensitive I sc . Both of these effects may reflect alterations in intracellular Ca been reported to inhibit ENaC activity by mechanisms that are not yet fully understood but may involve PKC (22) . A biphasic inhibition of ENaC by intracellular Ca 2ϩ has been described with time constants of ϳ2 min and 2 h (25). The acute effect probably reflects a reduction in channel open probability, whereas the delayed effect may be caused by a reduction of ENaC protein abundance (40) . In microdissected rat cortical collecting ducts, an increase in intracellular Ca 2ϩ (32) and pharmacological activation of PKC (19) have been shown to rapidly (within minutes) inhibit ENaC activity in cell-attached patches. This time course of inhibition is compatible with that observed in the present study. Therefore, both the Cl Ϫ secretory response and inhibitory effect on ENaC may be caused by increased intracellular Ca 2ϩ elicited by norepinephrine. The initial amiloride-insensitive peak response is consistent with previously reported findings of Cl Ϫ secretion in M-1 mouse cortical collecting duct cells (11) . However, a subsequent sustained stimulatory response to norepinephrine on ENaC activity was not observed in M-1 cells. This may be due to technical limitations that did not allow the measurement of I sc over a time period of several hours. Furthermore, M-1 cell culture medium contains high concentrations of dexamethasone, which likely maximally stimulate ENaC, thereby limiting any additional stimulatory effect of norepinephrine.
The mCCD cl1 cells used in the present study offer an improved model of principal cells. They respond to physiological concentrations of aldosterone, insulin, and AVP (20, 21, 24) , thereby allowing experimental conditions closer to the in vivo situation. In the present study, we confirmed that aldosterone robustly stimulates I sc and that this effect was greater and had a slower time course than that of norepinephrine. This suggests that the underlying molecular mechanisms mediating these effects are different. The mechanisms by which aldosterone stimulates ENaC are highly complex, but it is well established that aldosterone causes an increase in the number of channels present at the cell surface (30) . Whether the sustained stimulatory effect of norepinephrine on ENaC also involves an increase in channel density in the apical membrane remains to be determined. The stimulatory component of norepinephrine in cells prestimulated with aldosterone was . ␣2A-and ␣2C-adrenoceptor transcripts detected in mCCDcl1 cells. Specific primers were used to detect the expression of ␣1-adrenoceptor subtypes (␣1A, ␣1B, and ␣1D; A) as well as ␣2-adrenoceptor subtypes (␣2A, ␣2B, and ␣2C; B). For each receptor subtype, the expected expression of transcripts was confirmed in tissue from the mouse brain, liver, or aorta, with water (H2O) as a negative (no-template) control. Both ␣2A-and ␣2C transcripts were detected in mCCDcl1 cells. C: primers recognizing ␤-ENaC were used as a control in mCCDcl1 cell samples.
reduced, and, interestingly, the transient inhibitory response to norepinephrine was more pronounced. This is perhaps not surprising, since ENaC inhibition by norepinephrine can be expected to cause a more prominent response in cells with high ENaC activity than in cells with low ENaC activity. Whether the observed transient ENaC inhibition by norepinephrine plays a physiological role remains to be determined.
The finding that the stimulatory effect of norepinephrine was reduced in cells prestimulated with aldosterone compared with the effect in nonstimulated cells is of particular interest. It suggests that increased sympathetic drive may enhance ENaCmediated Na ϩ absorption, particularly in patients with suppressed plasma aldosterone levels. Thus, in these patients, an increased renal sympathetic drive resulting in a norepinephrine-induced activation of ENaC may contribute to the development of arterial hypertension. These patients may benefit from therapeutic interventions to reduce renal sympathetic drive or to reduce ENaC activity. In this context, it should be mentioned that renal denervation has been proposed as a treatment option for resistant hypertension (16, 27) . However, a recently completed trial with 535 randomized patients (Symplicity HTN-3) did not show a significant reduction of systolic blood pressure in patients with resistant hypertension 6 mo after renal artery denervation compared with sham control (6) .
In theory, inhibitors that specifically target tubular ␣ 2 -adrenoceptors may provide a novel therapeutic approach to prevent ENaC stimulation by norepinephrine. To our knowledge, such inhibitors are unavailable at present. Moreover, ␣ 2 -adrenoceptors are expressed in many tissues. Therefore, a drug applied systemically to inhibit ␣ 2 -adrenoceptors can be expected to have many side effects. In contrast, the clinical use of drugs inhibiting renal ENaC activity is well established. Spironolactone indirectly inhibits ENaC activity by preventing the stimulatory effect of the mineralocorticoid receptor, whereas the diuretic amiloride inhibits ENaC directly by blocking the channel pore. Both drugs are known as K ϩ -sparing diuretics and have been shown to be efficient antihypertensive drugs, particularly in patients with salt-sensitive hypertension (37) .
In conclusion, we have demonstrated that the sympathetic transmitter norepinephrine can stimulate Na ϩ absorption via ENaC in a mammalian model of cortical collecting duct principal cells. Appropriate regulation of ENaC activity in the ASDN is known to be important for the long-term control of arterial blood pressure. Therefore, under pathophysiological conditions, an increased renal sympathetic drive may contribute to the development of arterial hypertension by norepinephrine-mediated ENaC stimulation. It is tempting to speculate that affected patients may benefit from a treatment approach to reduce sympathetic drive or from drugs that inhibit ENaC activity. Fig. 7 . Adrenergic nerve fibers localize in close proximity to an ENaC-positive tubule in kidney slices. A: immunofluorescent staining of a section from mouse kidney. Shown is the distribution of ␤-ENaC (green), indicating principal cells of the aldosterone-sensitive distal nephron and tyrosine hydroxylase (red) as a marker of sympathetic nerve terminals typically associated with arterioles. Note the close proximity of some sympathetic varicosities to the basal aspect of epithelial cells. B: branch of the renal artery at the hilum surrounded by tyrosine hydroxylase-positive adrenergic nerve fibers (red). C: preabsorption control of the tyrosine hydroxylase antibody on the same artery in a consecutive section. Tyrosine hydroxylase immunostaining was drastically reduced due to preabsorption of the antibody with the respective antigen. Green autofluorescence of the membrana elastica interna and renal tubuli are included for orientation. Single confocal optical sections are shown. 
